Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure[5] - The company's SCD therapy targets the upstream source of effector cells and neutralizes effector cells that release cytokines[28] - The SCD conveniently connects with existing continuous kidney renal therapy that is widely available in U S ICUs today[36] Clinical Data and Approvals - QUELIMMUNE is approved by the FDA as a Humanitarian Use Device (HUD) to treat pediatric patients with acute kidney injury and sepsis or septic condition weighing 10 kilograms and requiring kidney replacement therapy[22] - QUELIMMUNE clinical data in pediatric acute kidney injury shows a 77% survival rate at Day 60 compared to 50% with standard of care[42] - In adult AKI studies, 87.5% of pediatric patients had normal kidney function at Day 60[45] Market Opportunity - The total US annual market opportunity for the Adult AKI market is ~$4.5 billion, which is 50 times the size of the Pediatric AKI market (~$100 million)[24] - The adult acute kidney injury population is 50x larger than the pediatric population[18] Financials - As of May 14, 2025, the company has a market capitalization of $13.5 million[69]

Financial Performance & Growth - OneWater Marine Inc achieved a 47% Compound Annual Growth Rate (CAGR) in Adjusted EBITDA and a 31% CAGR in Revenue from FY17 to FY23[11, 42] - In Q3 2024, total revenue was $542441 thousand, a decrease of 87% year-over-year compared to $594339 thousand in Q3 2023[62] - Adjusted EBITDA for Q3 2024 was $39206 thousand, a decrease of 366% compared to $61883 thousand in Q3 2023, with a margin of 72%[62] - Net income for Q3 2024 was $16714 thousand, a decrease of 498% compared to $33290 thousand in Q3 2023[62] Acquisition Strategy & Returns - The company aims to acquire dealerships at less than 40x EV/EBITDA and double their EBITDA within 24 months[23] - Acquisitions from FY16 to FY22, with a combined purchase price of $386 million and preacquisition EBITDA of $78 million, generated $135 million in FY23 EBITDA, resulting in a 35% Return on Invested Capital (ROIC) and a 29x FY23 EV/EBITDA multiple[23, 24] - Acquisitions from FY16 to FY18, with a combined purchase price of $72 million and preacquisition EBITDA of $16 million, generated $58 million in FY23 EBITDA, resulting in an 80% ROIC and a 13x FY23 EV/EBITDA multiple[25, 26] Revenue Streams & Inventory - New boat sales contribute 50% to revenue and 64% to gross profit, while pre-owned boat sales contribute 10% to revenue and 14% to gross profit[21] - Finance & Insurance contribute 3% to revenue and 17% to gross profit, while service, parts, and other contribute 16% to revenue and 26% to gross profit[21] Market Position & Footprint - The company has retail locations across 16 states, with 12 of those states being in the top 20 boating states[18]

Ondas Autonomous Systems (OAS) - OAS is positioned to achieve at least $20 million in expected revenues for 2025, entering the year with a $10 million backlog[22] - The company anticipates generating $25 million in revenue in 2025[23] - The combined Total Addressable Market (TAM) for Iron Drone Raider and Optimus System is estimated at $53 billion and $22 billion, respectively[27] - Initial Obtainable Market (SOM) through 2026 for Iron Drone is $70 million and for Optimus is $50 million[31] - Secured ~$144 million in purchase orders in Q3 2024[32] Ondas Networks - The total addressable market for private wireless Rail networks in North America is in excess of $13 billion[78] - Railroads could potentially drive ~$5 billion of additional revenue with a ~5% productivity increase[75] Financial Performance (Q1 2025) - Net revenues increased to $4248182, a 580% increase compared to $625009 in the same period last year[103, 104] - The company has a cash balance of $254 million, compared to $146 million a year ago[105, 106] - Holdings Convertible Debt reduced by $192 million to $254 million at the end of Q1 2025[108]

2024 Accomplishments - Natural gas prices averaged $1.98 per Mcf, a 30-year low excluding 2020[6] - The company increased its hedging program, improving realized gas price by 20% in 2024 and targeting 50% of expected production for 2025 and 2026[6] - The company added $100.5 million through an equity private placement and enhanced liquidity with a $400 million senior notes offering[6] - The company more than doubled its Western Haynesville acreage by adding 265,000 net acres at a cost of $401 per acre[6] - The company's drilling program replaced 170% of 2024 production and drove 6% reserve growth with 899 Bcfe of drilling related proved reserve additions, achieving an overall finding cost of $1.00 per Mcfe[6] Drilling and Efficiency - The company completed its first horseshoe well, the Sebastian 11 5, with a 9,382-foot lateral and a 31 MMcf per day initial production rate[11] - D&C costs for two 9,200-foot horseshoe laterals is $32 million or $1,740 per lateral foot, resulting in D&C Savings of $530 per lateral foot or 23%[11] - 13 operated Legacy Haynesville wells were turned to sales in Q1 2025 with an average lateral length of 12,367 ft and an average IP rate of 24 Mmcf/d[25] - One operated Western Haynesville well was turned to sales in Q1 2025 with a lateral length of 10,306 ft and an IP rate of 41 Mmcf/d[29] Financials and Outlook - The company spent $902 million in 2024 to add 899 Bcfe of Proved Reserves achieving all in finding costs of $1.00 per Mcfe[58] - As of March 31, 2025, the company had $33 million in cash and cash equivalents and $3.099 billion in total debt[62] - The company has strong financial liquidity of $1.0 billion[73]

Company Overview - Gladstone Land owns 150 farms with approximately 103,000 acres in 15 states and over 55,000 acre-feet of water assets in California, with 95.9% occupancy[10] - The company focuses on farmland growing fresh produce and permanent crops[11, 16] - Gladstone Land is managed by an SEC-registered investment advisor with over $4 billion of assets under management[12] Market Opportunity and Investment Focus - The company primarily focuses on acquiring high-value farmland that generates above-average revenues and profits[35] - The company targets transaction sizes between $2 million to $50 million+[43] - From 1980 through 2024, the Fresh Fruits & Vegetables segment of the Food & Beverages category increased by 385%[45] - U.S farmland value is approximately $3.4 trillion, with approximately 63% of U.S farm operators are over 55 years of age[65] Financial Performance - Since its IPO in 2013, the company has made 147 consecutive monthly cash distributions to common shareholders, totaling $7.32 per share[76] - Over the past 41 quarters, the company has increased the common distribution rate 35 times for a total increase of 55.7%[76] - The company's weighted-average remaining lease term is 6.7 years[83] - The company's weighted-average debt maturity is 7.4 years with a weighted-average effective interest rate of 3.41%, fixed for 3.5 years[84]

Financial Performance & Growth - Black Hills Corp achieved a solid financial position with a long-term EPS growth target of 4% to 6% off the 2023 base of $3.75 per share[9] - The company targets a 55%-65% dividend payout ratio and has increased its annual dividend for 55 consecutive years[9] - The company is delivering on 2025 earnings guidance, which represents ~5% year-over-year growth, achieving 4%-6% CAGR off 2023 base[11] Capital Investment & Infrastructure - Black Hills Corp has a five-year capital forecast of $4.7 billion for 2025-2029, a 10% increase from the prior five-year plan[11] - The company's capital investment plan includes $2.4 billion for electric utilities and $2.1 billion for gas utilities[93] - The company is undertaking the Ready Wyoming Electric Transmission Initiative, a 260-mile expansion project costing $350 million[33] Data Center & Customer Growth - Black Hills Corp announced 1 GW of data center demand from existing customers, with ~500 MW in the current plan requiring minimal capital[11] - The company expects data center EPS contribution to more than double to 10%+ by 2028[17] - The company's customer count growth is more than double the population growth, with a customer count CAGR of 1.1% from 2019-2024[20, 23] Regulatory & Sustainability - The company is actively executing three to four rate reviews per year, including a filed rate review for Kansas Gas requesting recovery of $17.2 million[11, 18] - Black Hills Corp is committed to reducing GHG emissions intensity 40% by 2030 and 70% by 2040 for electric utilities (2005 baseline)[110] - The company targets Net Zero GHG emissions by 2035 for the natural gas distribution system[110]

Financial Performance - Huntington's total assets reached $183 billion in 2024[25] - Total deposits amounted to $148 billion in 2024[27] - Total loans reached $120 billion in 2024[29] - Pre-Provision Net Revenue (PPNR) was $2.9 billion in 2024[31] - Return on Tangible Common Equity (ROTCE) was 15.7% in 2024[33] - Adjusted ROTCE was 16% in 2024[33] - The company's Net Charge-off Ratio was 0.30% in FY2024[44] - The company's Allowance for Credit Losses (ACL) was 1.88%[44] Growth & Strategy - Consumer and Business Primary Banking Relationships (PBRs) grew 2% and 3% year-over-year respectively[22] - Adjusted noninterest income increased by 10% year-over-year, reaching $2080 million[40]

Company Overview - NextPlat operates a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide[4] - The company is listed on the Nasdaq Capital Market under the tickers NXPL (Common Stock) and NXPLW (Warrants)[6] - As of March 31, 2025, NextPlat had 26 million common shares outstanding[6] - The company's market capitalization was $20.1 million as of July 1, 2025[6] Financial Performance - NextPlat reported $65.5 million in consolidated revenues for the year ended December 31, 2024, representing a 73% increase compared to the prior year[6, 52] - The company had $17.7 million in cash as of March 31, 2025[6, 55] - For the quarter ended March 31, 2025, NextPlat reported $14.525 million in net revenue[55] - Net loss attributed to common stockholders for the quarter ended March 31, 2025, was $1.343 million[55] Strategic Initiatives - NextPlat is focused on high-growth sectors, including technology, healthcare, and consumer wellness[7, 10] - The company leverages global online storefronts and offers turn-key access to high-barrier markets like China[8, 9] - NextPlat is expanding its offerings through strategic investments/acquisitions, licensing, or partnering with brands in high-growth sectors[17]

Dorzagliatin Overview - Dorzagliatin is a first-in-class drug with global rights, targeting the underlying cause of Type 2 Diabetes (T2D) by addressing impaired glucose homeostasis[13] - As of December 31, 2019, Hua Medicine had RMB 1.1 billion in cash[13] - The global T2D population is 453 million, with 120 million in China alone, representing a massive market opportunity[13] Clinical Trial Results - In a Phase III monotherapy trial, dorzagliatin achieved the primary endpoint, demonstrating a significant and sustainable reduction in HbA1c safely[13] - In the HMM0301 Phase III trial, the dorzagliatin-treated group showed a 1.07% HbA1c reduction from a baseline of 8.35%, compared to a 0.5% reduction from a baseline of 8.37% in the placebo group (p < 0.0001)[62] - 45.4% of patients treated with dorzagliatin achieved a target HbA1c level of 7.0% or less at 24 weeks, compared to 21.5% of patients treated with placebo (p < 0.0001)[62] - Patients treated with dorzagliatin achieved a homeostasis control rate of 45.0% compared with 21.5% in the placebo group (p < 0.0001)[62] Combination Therapy - A Phase I trial (HMM0111) showed that dorzagliatin combined with sitagliptin (DPP-4 inhibitor) resulted in a 33% reduction (p<0.01) in postprandial glucose level AUEC (0-4hr)[74] - A Phase I trial (HMM0112) showed that dorzagliatin combined with empagliflozin (SGLT-2 inhibitor) resulted in a 38% reduction (p<0.0001) in postprandial glucose level AUEC (0-4hr)[79] China Market - China has the largest diabetes population globally, with approximately 125 million T2D patients[232] - The diagnosis rate in China was 50.4% in 2018 and is expected to rise to 82.2% in 2028[235] - The China anti-diabetics market is projected to grow from RMB 57.3 billion in 2018 to RMB 135.6 billion in 2025, with an expected CAGR of 11.7% from 2018 to 2028[246]

Company Performance & Strategy - Newell's net sales were $7.6 billion [9] - Approximately 90% of sales are attributed to 25 brands [9] - International sales account for 38% of total sales [9] - In 2024, the company implemented a new corporate strategy based on a capability assessment conducted in 2023 [17, 39, 102, 146] - The company is focused on its top 10 brands [30] Financial Improvements & Outlook - TTM normalized EBITDA was $884 million as of Q1 2025 [9] - TTM Normalized Gross Margin percentage is 31.9%, reflecting a +610 bps increase [113] - Operating cash flow improved by over $750 million from FY22 to FY24 [138] - The company reduced net debt by approximately $175 million in 2024 [138] - The leverage ratio decreased from 5.8x in FY23 to 4.9x in FY24 [140] Supply Chain & Cost Optimization - China to US sourcing has been reduced from 35% to less than 10% by the end of 2025 [91] - The company has reduced its supply base by approximately 45% since 2020 [122] - Transportation costs decreased by 40 bps in 2024 [114, 126] - Headcount has been reduced by 14% since 2022 [132]